CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 14 enrolled
Drug / intervention
Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®biological
Likely dose
Combined measles-mumps-rubella (MMR) vaccine - PRIORIX® 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02325310
NCT02325310Phase 4Completed
CompareCT.gov

Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With a Combined Measles-mumps-rubella (MMR) Vaccine

Assistance Publique - Hôpitaux de Paris·interventional·Posted Dec 24, 2014·Updated Mar 30, 2026

In Brief

A Phase 4 clinical trial evaluating Combined measles-mumps-rubella (MMR) vaccine - PRIORIX® for Measles and 2 related conditions. Completed, enrolled 14 participants across 1 site.

Detailed Summary

In order to assess the safety of breastfed infants after their mother's postpartum immunization with a combined measles-mumps-rubella (MMR) vaccine, the purpose of this study is to investigate whether measles vaccine strain is excreted in breast milk of breastfeeding women with negative rubella and measles serologies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeasles, Rubella, Mumps
CountriesFrance
CollaboratorsService de Bactériologie-Virologie-Hygiène, CHU Limoge, GO-CIC network (Réseau Gynéco-Obstetrical des Centres d'Investigation Clinique), REIVAC network (Réseau National d'Investigation Clinique en Vaccinologie), URC-CIC Paris Descartes Necker Cochin

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 24, 2014
Enrollment StartFeb 4, 2015
Primary CompletionMay 3, 2016
Study CompletionNov 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 11.5 years ago

Interventions

Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®biological

One dose of 0.5 mL vaccine will be administered (intra-muscularly or subcutaneous) in post-partum (before the exit of the maternity) during visit V0. A second dose will be administered at week 8(+/-15 days) during visit V1.